Pathway-based biomarker search by high-throughput proteomics profiling of secretomes.
暂无分享,去创建一个
Paul Tempst | Josep Villanueva | Lynne Lacomis | P. Tempst | J. Villanueva | K. Lawlor | Arpi Nazarian | Kevin Lawlor | Arpi Nazarian | L. Lacomis
[1] Chun-Ming Huang,et al. Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. , 2008, Journal of proteome research.
[2] S. Carr,et al. Examination of micro-tip reversed-phase liquid chromatographic extraction of peptide pools for mass spectrometric analysis. , 1998, Journal of chromatography. A.
[3] Michael K. Coleman,et al. Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae. , 2006, Journal of proteome research.
[4] Alexey I Nesvizhskii,et al. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.
[5] D. Hanahan,et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. , 2006, Genes & development.
[6] R. Keri,et al. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-β signaling in ErbB2/Neu-induced tumors from transgenic mice , 2005, Oncogene.
[7] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[8] B. Searle,et al. Improving sensitivity by probabilistically combining results from multiple MS/MS search methodologies. , 2008, Journal of proteome research.
[9] P. Tempst,et al. A Sequence-specific Exopeptidase Activity Test (SSEAT) for “Functional” Biomarker Discovery*S , 2008, Molecular & Cellular Proteomics.
[10] D. Fuchs,et al. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. , 2003, The American journal of pathology.
[11] M. McMahon,et al. Extracellular Signal-regulated Kinase (ERK)-dependent Gene Expression Contributes to L1 Cell Adhesion Molecule-dependent Motility and Invasion* , 2004, Journal of Biological Chemistry.
[12] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[13] J. Pollard,et al. Macrophages: modulators of breast cancer progression. , 2004, Novartis Foundation symposium.
[14] R. Aebersold,et al. A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.
[15] S. Hankinson,et al. Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.
[16] P. Tempst,et al. Correcting common errors in identifying cancer-specific serum peptide signatures. , 2005, Journal of proteome research.
[17] D. Fenyo,et al. Phosphotyrosine Signaling Networks in Epidermal Growth Factor Receptor Overexpressing Squamous Carcinoma Cells*S , 2005, Molecular & Cellular Proteomics.
[18] Bert Vogelstein,et al. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies , 2006, Nature Biotechnology.
[19] V. Hwa,et al. IGFBPs and cancer. , 2004, Novartis Foundation symposium.
[20] K. Kinzler,et al. Cancer genes and the pathways they control , 2004, Nature Medicine.
[21] Allison Jones,et al. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells , 2003, Oncogene.
[22] S. Werner,et al. Active Caspase-1 Is a Regulator of Unconventional Protein Secretion , 2008, Cell.
[23] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[24] A. Olshen,et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.
[25] L. Beaulieu,et al. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.
[26] Troels Z. Kristiansen,et al. Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach*S , 2006, Molecular & Cellular Proteomics.
[27] Adam S. Kibel,et al. Integrative molecular concept modeling of prostate cancer progression , 2007 .
[28] F. Abdul-Karim,et al. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors , 2006, Oncogene.
[29] I. Beavon. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. , 2000, European journal of cancer.
[30] J. Beattie,et al. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. , 2006, The Biochemical journal.
[31] N. Bruchovsky,et al. Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways* , 2002, The Journal of Biological Chemistry.
[32] N. Blom,et al. Feature-based prediction of non-classical and leaderless protein secretion. , 2004, Protein engineering, design & selection : PEDS.
[33] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Weinstein,et al. Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.
[35] R. Hargreaves,et al. Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.
[36] Steven A Carr,et al. Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.
[37] E. Diamandis,et al. Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines , 2007, Molecular & Cellular Proteomics.
[38] Carl W. Miller,et al. Functional domains of CCN 1 ( Cyr 61 ) regulate breast cancer progression , 2022 .
[39] S. Hanash,et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study , 2006, Nature Biotechnology.
[40] L. Pannell,et al. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. , 2007, Journal of proteome research.
[41] S. Brunak,et al. SHORT COMMUNICATION Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites , 1997 .
[42] M. Waters,et al. of Insulin-Like Growth , 1993 .
[43] Bonnie F. Sloane,et al. Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.
[44] K. Dolinski,et al. Use and misuse of the gene ontology annotations , 2008, Nature Reviews Genetics.
[45] P. Tam,et al. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma , 2004, Oncogene.
[46] Jeffrey T. Chang,et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.
[47] A. Musti,et al. Multiple Members of the Mitogen-activated Protein Kinase Family Are Necessary for PED/PEA-15 Anti-apoptotic Function* , 2002, The Journal of Biological Chemistry.
[48] W. Schmiegel,et al. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer , 2005, Proteomics.
[49] V. Castronovo,et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. , 2007, Cancer research.
[50] G. Landreth,et al. Activation of the MAPK Signal Cascade by the Neural Cell Adhesion Molecule L1 Requires L1 Internalization* , 1999, The Journal of Biological Chemistry.
[51] B. Binder,et al. The plasminogen activator inhibitor "paradox" in cancer. , 2008, Immunology letters.
[52] S. Horvath,et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer , 2007, Proceedings of the National Academy of Sciences.
[53] Rameen Beroukhim,et al. Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.
[54] N. Anderson,et al. The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.
[55] C. Sawyers. The cancer biomarker problem , 2008, Nature.
[56] J. Baselga,et al. Targeting Tyrosine Kinases in Cancer: The Second Wave , 2006, Science.
[57] A. Ullrich,et al. Strategies to overcome resistance to targeted protein kinase inhibitors , 2004, Nature Reviews Drug Discovery.
[58] Y. Sakata. Plasminogen activator inhibitor , 1986 .
[59] K. Resing,et al. Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics*S , 2005, Molecular & Cellular Proteomics.
[60] Chris Cheadle,et al. Application of z-score transformation to Affymetrix data. , 2003, Applied bioinformatics.
[61] David Sidransky,et al. Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.
[62] M. Mann,et al. Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.
[63] F. Blasi,et al. The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy , 2003, Cancer and Metastasis Reviews.
[64] Harald Sontheimer,et al. Neuregulin-1 Enhances Motility and Migration of Human Astrocytic Glioma Cells* , 2003, Journal of Biological Chemistry.